Soligenix, Inc.

SNGX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.401

+$0.0209 · +5.50%

Aug 21, 4:00 PM ET

Pre-market

$0.3961

−$0.0049 · -1.22%

Aug 24, 4:05 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

32/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Fair Value

Momentum

Strong Down

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $0.401

$0.3924$0.4219

52-week range

Current $0.401

$0.28$3.36

Open: $0.3924
Previous close: $0.3801
Volume: 989.18K
Market cap: 5.94M USD
50-day average: $0.3844; +4.32% above average
200-day average: $0.9407; -57.37% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -0.32×
P/B (TTM): 0.96×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.05×
Altman Z-score: -35.08
Piotroski F-score: 2 of 9

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

8 ratings

Strong buy00%

Buy563%

Hold338%

Sell00%

Strong sell00%

SNGX news

prnewswire.comAug 7, 2026

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there…

Read source

feeds.newsfilecorp.comJun 26, 2026

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors

Read source

prnewswire.comJun 8, 2026

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix…

Read source

prnewswire.comMay 26, 2026

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or…

Read source

Corporate actions

Corporate action history

Action	Effective date	Details	Record date	Payment date
Stock split	Jun 6, 2024	1:16	—	—
Stock split	Feb 10, 2023	1:15	—	—
Stock split	Oct 7, 2016	1:10	—	—
Stock split	Feb 1, 2012	1:20	—	—
Stock split	Jun 11, 1997	1:15	—	—
Stock split	Dec 6, 1995	1:100	—	—

Stock split

Effective Jun 6, 2024